Abstract: Electrically conductive carbon flakes and films are prepared in high yield by the pyrolysis of cyclic aromatic hydrocarbons, optionally halogenated, in the presence of a dehydrogenating agent at about at least 800.degree. C. Flakes of thicknesses up to 20 .mu.m and lengths up to 1 cm on a side are metal-like in appearance and have a conductivity of about 200-300 S/cm at room temperature. By heat treatment to 2600.degree. C., graphitic order is improved and the conductivity rises to .apprxeq.10000-15000 S/cm.
Abstract: An insecticidal composition in the form of a hydrated macrogel containing at least one species of entomopathogen and a hydrated water retentive compound which acts as a water-reservoir for the entomopathogen. Optionally, the macrogel contains attractants, in particular raffinose and gamma-irradiated, fungal-decayed wood.
Abstract: A microcapsule comprising an aqueous core, and capsular membrane formed from the interfacial reaction product of a hydrophilic polymeric Lewis acid or salt thereof with a lipophilic Lewis base or salt thereof.
Abstract: The present invention is directed to new artificial base pairs comprising complementary artificial purines and pyrimidines and methods of using artificial complementary base pairs.
Abstract: A multiple lumen catheter specifically adapted for selective visualization of one or the other of the coronary arteries. One lumen of the multiple lumen catheter is adapted to deliver contrast agent to the coronary artery to be visualized while a second, and optionally a third, lumen is adapted to limit flow of contrast agent to one or more other locations in the aortic root complex. The invention also includes a method of preparing for coronary angiography using such a catheter.
Abstract: A composition and method for nasal administration of pharmaceuticals utilizes glycyrrhetinic acid as an absorption enhancer. The composition comprises an effective amount of the pharmaceutically active substance, glycyrrhetinic acid, in an amount effective for enhancing permeation of the active substance across the nasal membrane, and a basic salt of an amino acid as an adjuvant. The composition may be administered to the nasal cavity in the form of a spray by using an atomizer, nebulizer, spayer, dropper or other device which ensures contact of the composition with the nasal mucus membrane.
Type:
Grant
Filed:
September 14, 1989
Date of Patent:
May 12, 1992
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: A container for a liquid crystal cumulative dosimeter including a resilient outer body sealed to confine a first liquid crystal composition constituent and a second liquid crystal composition constituent and having at least one transparent section to permit observation of the color of the confined composition, and a barrier contained completely within and physically unattached to the outer body for separating the first constituent from the second constituent, whereby disruption of the barrier allows the first constituent to mix with the second constituent. The barrier is formed either by encapsulating one or both of the constituents or by using air bubbles. Methods of manufacturing the various containers shown and processes of using those containers are also disclosed.
Abstract: A device consisting of a wire for occluding an aperture within a body surface, such as atrial and ventricular septal defects (and the method of using such a device). The wire comprises two configurations, an elongated configuration for passage into said body through a catheter and through the aperture, and a preprogrammed configuration including occlusion-forming wire segments, one on each side of said aperture. The wire also includes means (preferably a temperature-induced shape change) for changing the wire from the elongated configuration to the preprogrammed configuration in the body.
Abstract: A tamper evident over-wrap is disclosed which employs a multi-layered system including three overlapping layers of containment material and two interleaved layers of reactive material, at least one of which is a gel. Upon formation of an opening of the middle layer of containment material, the previously-isolated layers of reactive material will intermingle and react. These materials react to form a color change. By using a gel, manifestations of tampering attempts are considerably enhanced.
Type:
Grant
Filed:
October 9, 1990
Date of Patent:
April 14, 1992
Assignee:
Temple University
Inventors:
Mortimer M. Labes, Ranganath Parthasarathy
Abstract: Oligonucleotides are provided having a nucleotide sequence complementary to at least a portion of the mRNA transcript of the human c-myb gene. These "antisense" oligonucleotides are hybridizable to the c-myb mRNA transcript. Such oligonucleotides are useful in treating hematologic neoplasms and in inducing immunosuppression. They are particularly useful as bone marrow purging agents.
Type:
Grant
Filed:
October 27, 1989
Date of Patent:
March 24, 1992
Assignee:
Temple University-of the Commonwealth System of Higher Education
Abstract: Improved sustained-release delivery forms comprising Lewis acid-Lewis base salt microparticulate material modified by the addition of at least one additional constituent known as an "adjuvant" selected from the group consisting of carbomers, poloxamers and tetronomers. Adjuvants may assist in the manufacture of the microparticle or may provide additional advantageous characteristics such as assisting in solubilizing a core material or forming of the microparticle wall or both. Adjuvant modified microparticles have improved controlled release characteristics, have greater mechanical and thermal stability and have increased capacity for a wide range of core materials.
Type:
Grant
Filed:
October 5, 1989
Date of Patent:
March 3, 1992
Assignee:
Temple University
Inventors:
Tully J. Speaker, Tycho J. Speaker, John H. Collett
Abstract: Trigramin, a 72-amino acid polypeptide, has the following amino acid sequence: EAGEDCDCGSPANPCCDAATCKLIPGAQCGEGLCCDQCSFIEEGTVCRIARGDDLDDYCNGRSAGCPRNPFH. The molecule is a potent inhibitor of fibrinogen binding to receptors expressed on the glycoprotein IIb/IIIa complex in the membrane of platelets. Trigramin is thus a potent inhibitor of fibrinogen-induced human platelet aggregation. It is useful in inhibiting the formation of hemostatic platelet plugs.
Type:
Grant
Filed:
September 19, 1990
Date of Patent:
November 19, 1991
Assignee:
Temple University of the Commonwealth System of Higher Education
Inventors:
Tur-Fu Huang, Stefan Niewiarowski, John C. Holt, Hanna Lukasiewicz
Abstract: Two novel cell lines, ATCC #HB-8963 and ATCC #HB-8964 produce monoclonal antibody to human kininogen. One of the antibodies specifically recognizes the heavy chain of high and low molecular weight kininogen (the later protein is identical to alpha cysteine protease inhibitor). The other antibody recognizes the light chain of high molecular weight kininogen. The hybridomas are formed by fusing spleen cells from immunized BALB/c AnSkh mice with P3X63Ag8 or SP2/0-Ag14 myeloma cells. Diagnostic, therapeutic and biochemical uses of the monoclonal antibodies are provided.
Type:
Grant
Filed:
October 30, 1989
Date of Patent:
September 10, 1991
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: Compounds of the formula ##STR1##REFERENCE TO GOVERNMENT GRANTThe invention described herein was made, in part, in the course of work supported by National Institutes of Health Grants GM 27210 and CA 29545, and National Science Foundation Grant PCM 84-15002.
Type:
Grant
Filed:
April 26, 1988
Date of Patent:
February 5, 1991
Assignee:
Temple University-of the Commonwealth System of Higher Education
Abstract: Novel 2-substituted trimethylpyrazine derivatives of the formula: ##STR1## wherein R is alkylamino, 4-methyl-1-piperazinyl, piperidino, morpholino or 2-trimethylpyrazinepropenyl.These novel 2-substituted trimethylpyrazine derivatives exhibit, at very low concentrations, activity as inhibitors of platelet function and as promoters of blood pressure reduction.
Type:
Grant
Filed:
April 11, 1989
Date of Patent:
December 18, 1990
Assignee:
Temple University of the Commonwealth System of Higher Education
Inventors:
Mark L. Nelson, Peter H. Doukas, Leon Salganicoff, Fiore J. Ricciardi
Abstract: Carbon-transition metal composite formed via pyrolytic decomposition of a polycyanogen in the presence of a transition metal or a salt thereof.
Abstract: Novel cell lines produce monoclonal antibody to the light chain region of human factor XII. Three such cell lines, ATCC #HB-9703 through ATCC #HB-9704, are formed by fusing SP2/0-Ag14 myeloma cells with spleen cells from BALB/c AnSkh mice immunized with human factor XIIf. Biochemical and therapeutic uses of the monoclonal antibodies are provided.
Type:
Grant
Filed:
June 9, 1988
Date of Patent:
October 16, 1990
Assignee:
Temple University of the Commonwealth System of Higher Education
Abstract: Optically active compounds of the formula ##STR1## wherein n is 1 or 2 and m is 0, 1, 2 or 3 have antiviral activity. Compounds of the formula wherein at least one of the internucleotide phosphorothioate linkages is of the Sp configuration possess increased antiviral activity and/or metabolic stability.
Type:
Grant
Filed:
October 22, 1987
Date of Patent:
May 15, 1990
Assignee:
Temple University-of the Commonwealth System of Higher Education
Inventors:
Robert J. Suhadolnik, Wolfgang Pfleiderer